153 results about "Mental illness" patented technology

Disclosed herein is a method for treating depression associated with alcoholism in a patient comprising administering to the patient a pharmacologically effective dose of an opioid antagonist, and a pharmacologically effective dose of at least one drug compound selected from the group consisting of a tricyclic antidepressant, an a-typical antidepressant, and lithium.

A neurological control system for modulating activity of any component or structure comprising the entirety or portion of the nervous system, or any structure interfaced thereto, generally referred to herein as a “nervous system component.” The neurological control system generates neural modulation signals delivered to a nervous system component through one or more neuromodulators, comprising intracranial (IC) stimulating electrodes and other actuators, in accordance with treatment parameters. Such treatment parameters may be derived from a neural response to previously delivered neural modulation signals sensed by one or more sensors, each configured to sense a particular characteristic indicative of a neurological or psychiatric condition.

A system for and method of remote monitoring, screening, assessment and treatment of patients having a mental health illness such as post-traumatic stress disorders or other traumatic stress injury and co-occurring symptomatology. Patients in constant communication with one or more healthcare professionals through a wireless network, complete executable programs on their patient handheld electronic devices and transmit the results of the executable programs to their supervising mental health professional. The mental health professionals review and analyze the collected patient data to make clinical assessments of the patients' mental health status.

The invention provides a man-machine motion interaction system and method based on expression recognition. The system comprises an image acquisition module, an image processing module, an expression recognition module, a man-machine interaction module and a storage module. The image acquisition module acquires a facial image; the image processing module processes the acquired facial image for graying, size adjustment and the like; an expression in the facial image is recognized by means of expression recognition; the man-machine interaction module feeds back to a user according to the facial expression; the statistical and storage module analyzes mental state of the user at this moment and records the mental state; meanwhile, a statistical query function is provided for the user. After applied to intelligent equipment, the system is capable of providing specific humanized responses so that the equipment can be more intelligent; when applied to mental care robots, the system is capable of capturing patients' expressions to allow for simple and effective communication with patients, so that the patients with mental illnesses can be supervised safely in real time, and effective data basis for treatment is provided for doctors.

The present invention relates to compounds of Formula I or II, or pharmaceutically acceptable salts, esters, or prodrugs thereof:

which relates to morphinan compounds useful as μ, δ, and/or κ receptor opioid compounds and pharmaceuticals containing same that may be useful for mediating analgesia, combating drug addiction, alcohol addiction, drug overdose, mental illness, bladder dysfunctions, neurogenic bladder, interstitial cystitis, urinary incontinence, premature ejaculation, inflammatory pain, peripherally mediated and neuropathic pain, cough, lung edema, diarrhea, cardiac disorders, cardioprotection, depression, and cognitive, respiratory, diarrhea, irritable bowel syndrome and gastro-intestinal disorders, immunomodulation, and anti-tumor agents.

The present invention relates to methods of treating of the underlying dysregulation of the emotional functionality of mental disorders (i.e. affect instability-hypersensitivity-hyperaesthesia-dissociative phenomena- . . . ) using compounds and compositions of compounds having D4 and/or 5-HT2A antagonistic, partial agonistic or inverse agonistic activity for. The invention also relates to methods comprising administering to a patient diagnosed as having a neuropsychiatric disorder a pharmaceutical composition containing (i) compounds having D4 antagonistic, partial agonistic or inverse agonistic activity and/or (ii) compounds having 5-HT2A antagonistic, partial agonistic or inverse agonistic, and/or (iii) any known medicinal compound and compositions of said compounds. The combined D4 and 5-HT2A antagonistic, partial agonistic or inverse agonistic effects may reside within the same chemical or biological compound or in two different chemical and/or biological compounds.

Disclosed are methods and systems for treatment planning for deep brain or superficial neuromodulation using ultrasound and other treatment modalities impacting one or multiple points in a neural circuit to produce acute effects or Long-Term Potentiation (LTP) or Long-Term Depression (LTD) to treat indications such as neurologic and psychiatric conditions. Ultrasound transducers or other energy sources are positioned and the anticipated effects on up-regulation and/or down-regulation of their direction of energy emission, intensity, frequency, firing/timing pattern, and phase/intensity relationships mapped onto the recommended treatment-planning targets. The maps of treatment-planning targets onto which the mapping occurs can be atlas (e.g., Tailarach Atlas) based or image (e.g., fMRI or PET) based. Atlas and imaged-based maps may be representative and applied directly or scaled for the patient or may be specific to the patient.

The present invention is a method and system for detecting linguistic markers as signs and indicators of mental illness, even prior to onset of symptoms of the mental illness. The linguistic markers may be detected in diachronic analyses of writing or speech samples. In particular, the present invention may identify lexical and syntactic changes in language due to mental illness. To recognize such changes the present invention may utilize complete, fully parsed texts or speech representing a number of measures. The identification of markers may provide a means of detecting mental illness early on based on a person's use of language. The language may be presented as spontaneous speech or writing, and may include samples of speech and/or writing occurring over time.

A diagnosis system and method comprising a handwriting data collection and analysis software and accompanying tools for diagnosing a given condition such as an illness, a mental illness, a physiological condition, a mental or emotional state, medication effect, a personality trait, a skill, an expertise, deception or truth writing. The handwriting of a control group known to have a condition is analyzed in order to determine the detectable characteristic indicators of that group. Such measured indicators comprise spatial, temporal and pressure measures for each writing stroke. The handwriting of a subject is then analyzed to determine if the measured indicators indicate statistically that the subject can be diagnosed with a condition.

Systems and methods for identifying genetic variations in a disease and diagnosing a patient with a mental illness, or a generic variant of same. The systems and methods use genomics and phenomics in a computer-implemented methods to identify biclusters in phenomic and genomic data, discover relationships among the biclusters, organize the relations into partitions, rank the predictive utility of features, and map the disease risk function. This can in turn be used to diagnose a patient in a person-centered fashion.

Disclosed are methods, systems, and devices for generating sleep predicators to avoid preventable mental episodes from breaking through, thereby averting an irreversible brain damage to a patient, that may be caused by such future mental episodes. In one embodiment, the present invention is a method comprising: acquiring biomedical data from a patient by using a means of signal acquisition; forming a database of the biomedical records in which the database further comprises a sleep prediction algorithm, psychiatric records, and a statistical engine to compute the data and the psychiatric records using the algorithm; mapping the acquired data in reference to the sleep prediction algorithm; validating the sleep predictors; and providing an output of the sleep predicators to a patient or caretaker. The present invention can be used to treat mania, depression, bipolar disorder, schizophrenia, PTSD, anxiety, and other chronic mental health conditions.

The invention discloses an emotion record, analysis and guidance system and an implementation method of the emotion record, analysis and guidance system. The emotion record, analysis and guidance system and the implementation method mainly solve the problems that an emotion guidance system with the function of preventing and reducing mental illness p in advance is not available in the prior art, and the requirement of people cannot be met. The implementation method includes the steps that an emotion management platform reads mood data of users and physiological data of the users collected by an emotion smart watch; the mood data of the users and the physiological data of the users are transmitted to a data processing center; the data processing center analyzes user information to acquire current emotion conditions of the users and stores the analysis result; when it shows that the users are in bad moods currently through analysis, the analysis result is fed back to the emotion management platform, and the emotion management platform automatically extracts funny pictures and/or jokes from a database and then sends the funny pictures and/or the jokes to user terminals. By the adoption of the scheme, the goal of preventing and reducing mental illness in advance is achieved, and the system has high practical value and promotional value.

Mental illness is a huge burden on those afflicted with it, as well as their caregivers and represents a major cost to society as a whole. The invention herein is concerned with methods and apparatus to improve the well-being of persons afflicted with mental illness, as well as to provide early and better diagnosis. It is felt that in some cases such diagnosis can lead to a potential for eliminating the worst effects of the illness altogether, by allowing intervention before a first psychotic episode occurs. The invention uses sensors, primarily 2D or 3D cameras and voice recognition to observe persons in many instances during ordinary activity such as playing video games, chatting on the internet or other such computer based activity.

This invention relates to compounds of formula I

their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R¹, R², R³ have meanings given in the description.

This invention relates to NAP-like and SAL-like peptide mimetics, polypeptides, or small molecules derived from them, and their use in the treatment of neuronal dysfunction, neurodegenerative disorders cognitive deficits, neuropsychiatric disorders, and autoimmune disease.

The invention discloses a deep brain stimulation electrode. The deep brain stimulation electrode comprises at least two groups of output electrode contacts; one or more output electrode contacts are arranged in each group of the output electrode contacts; one or more output electrode contacts of the first group of the output electrode contacts are arranged at the brain nucleus accumbens septi part after the output electrode contacts are mounted; one or more output electrode contacts of the second group of output electrode contacts are arranged at the brain internal capsule anterior limb part after the output electrode contacts are mounted. The invention further discloses a deep brain stimulation device provided with the electrode, and a deep brain stimulation method used for drug rehabilitation. According to the invention, simultaneous combined stimulation to the nucleus accumbens septi and the internal capsule anterior limb difunctional areas is realized by one electrode; specific stimulation can be conducted on different brain functional areas; the availability and safety of the deep brain electric stimulation on abstinence of drugs, and treatment of psychogenic illnesses of obsessive-compulsive disorder, depressive disorder, and the like are improved.

The invention relates to a psychological testing treatment system based on virtual reality. The psychological testing treatment system comprises a reality testing system, a VR testing treatment systemand a background server system. The reality testing system is internally provided with a VR positioning unit. The reality testing system further comprises VR helmet type glasses and a VR handle. TheVR testing treatment system comprises a virtual scene which is arranged and a VR treatment island, wherein the VR treatment island comprises a plurality of testing treatment units. The background server system comprises an information collecting system, an information storage system and a control system. According to the system, standard, systematical and scientific detecting technology is combined with metal disease treatment, thereby establishing a virtual model which can detect and treat the metal disease, and forming a detecting and treating method so that interactive design of the patientis realized in the virtual scene, thereby realizing high pertinency in testing and treatment and satisfying the testing requirements of different patients.

The invention discloses an online triage management method and system for mental illness and belongs to the mental illness triage management field. The method comprises steps that S1, a psychiatrist and a helper register separately to log into the system; S2, the helper checks a demand option through the system prompt, and the psychiatrist who meets the needs to complete the triage is automatically searched by the system; S3, the helper and the psychiatrist corresponding to the triage perform real-time video consultation; S4, after the consultation content is archived by the system, a mental health electronic file is further generated, the information is sent to the psychologist when the helper consults again according to the file; and S5, the psychiatrist is evaluated by the helper. The method is advantaged in that problems that psychologist resources are scarce and unevenly distributed, the offline mental illness medical treatment time is conflicted, the function of a consultation platform is single, and the psychological disease consultation effect is not good due to too-high cost in the prior art are solved, reasonable allocation of the psychologist resources is achieved, easyand quick consultation is promoted, and the consultation effect is improved.

Pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and alprazolam are disclosed. Methods of using the pharmaceutical compositions for treating patients suffering from one or more psychiatric disorders such as major depressive disorder, generalized anxiety disorder, panic disorder, agitation, social anxiety disorder, mild chronic depression, obsessive-compulsive disorder, premenstrual dysphoric disorder, seasonal affective disorder, dysthymia, childhood enuresis, bipolar disorder, posttraumatic stress disorder, sleep disorder related to anxiety, are also disclosed.

The invention discloses a mood state self-rating system based on an electronized POMS self-rating scale. The system comprises a smart phone and a background cloud server. The independently developed electronized POMS self-rating scale is installed in the smart phone, scale data sent by the smart phone is received by the background cloud server, a mood state evaluating algorithm is operated, and an obtained main mood state and the change rule thereof, different mood state daily change rules of a user, total mood quantitative evaluation and other results are sent to the smart phone and fed back to the user. The electronized self-rating scale is operated through a sliding block, a button and other assemblies, the easy and convenient operation is suitable for daily mental state evaluation of mental patients and further consultation patients suffering from depression, mania, anxiety and the like, the treatment compliance of the patients is improved, mental state evaluation services can be provided for normal users in the environments of families and communities, and the accessibility of mental health medical treatment services is improved.

Embodiments of the present invention provide methods for diagnosing schizophrenia, schizo-affective disorder and/or psychosis in an individual or predicting risk of the individual developing schizophrenia, schizo-affective disorder or psychosis, by determining values for one or more markers in each of five domains, namely a neurotransmitter domain, an oxidative stress domain, a nutrition-biochemistry domain, a visual processing domain and an auditory processing domain.

The present invention comprises novel methods for the use of compositions comprising 7-keto DHEA for treating psychiatric conditions. These methods include administering an effective amount of a composition comprising 7-keto DHEA in an acceptable carrier, alone or in combination with other psychiatric drugs, such as analgesic agents, anticonvulsants, anti-anxiety agents, antidepressants, anti-panic agents, antipsychotic agents, bipolar agents, psychostimulants to reduce or ameliorate symptoms of a psychiatric condition. This method may be used alone or as an adjunctive treatment for treating a wide variety of psychiatric conditions such as stress disorders, anxiety disorders and depressive disorders.